Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zealand Pharma's 'More Commercial' CEO Jensen On Lixisenatide And Beyond

This article was originally published in Scrip

Executive Summary

Danish company Zealand Pharma, most noteworthy for developing the thus far commercially disappointing Sanofi-partnered GLP-1 receptor agonist Lyxumia (lixisenatide), appointed its new CEO a year ago, claiming it needed someone with a more commercial focus. Scrip caught up with Britt Meelby Jensen to find out what lessons the company has learned from the Lyxumia episode and how Zealand Pharma is moving beyond diabetes.

You may also be interested in...



Finance Watch Public Company Edition: Akcea, Kala Launch IPOs While FOPOs Keep Busy Pace

Kala follows July's first biopharma IPO from Ionis spinout Akcea into the stock market. Amicus, Arena and othera go high with major offerings, while Inovio and Regulus go low. Also, Galena, Neothetics provide updates on their hunts for "strategic alternatives."

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Topics

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel